Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EVOK 
Evoke Pharma Inc (EVOK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: EVOK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18
1 Year Target Price $18
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.38% | Avg. Invested days 21 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.06M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 1 | Beta -0.13 | 52 Weeks Range 1.94 - 9.88 | Updated Date 09/15/2025 |
52 Weeks Range 1.94 - 9.88 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -42.07% | Operating Margin (TTM) -41.55% |
Management Effectiveness
Return on Assets (TTM) -23.67% | Return on Equity (TTM) -152.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1126989 | Price to Sales(TTM) 0.63 |
Enterprise Value 1126989 | Price to Sales(TTM) 0.63 | ||
Enterprise Value to Revenue 0.09 | Enterprise Value to EBITDA -0.36 | Shares Outstanding 1558460 | Shares Floating 1390367 |
Shares Outstanding 1558460 | Shares Floating 1390367 | ||
Percent Insiders 1.28 | Percent Institutions 25.39 |
Upturn AI SWOT
Evoke Pharma Inc
Company Overview
History and Background
Evoke Pharma Inc. is a specialty pharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) disorders. Founded in 2007, the company has focused primarily on developing and commercializing GIMOTI, a nasal spray formulation of metoclopramide.
Core Business Areas
- Commercialization of GIMOTI: Evoke Pharma's core business is centered around the commercialization of GIMOTI (metoclopramide) nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Leadership and Structure
Matt D'Onofrio serves as the CEO of Evoke Pharma Inc. The organizational structure includes departments for sales, marketing, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- GIMOTI: GIMOTI is Evoke Pharma's primary product. It's a nasal spray formulation of metoclopramide used to treat gastroparesis. Market share data for GIMOTI is limited due to competition and relatively recent launch, but competes with oral metoclopramide generics and other prokinetic agents. Competitors include generic manufacturers of oral metoclopramide and other drugs like domperidone (not available in the US).
Market Dynamics
Industry Overview
The gastrointestinal pharmaceutical market is characterized by a high prevalence of GI disorders and a growing demand for effective treatments. The market includes various therapeutic areas, such as acid reflux, irritable bowel syndrome (IBS), and gastroparesis.
Positioning
Evoke Pharma aims to differentiate itself through the nasal delivery of metoclopramide, which bypasses the GI tract and may offer advantages for patients with gastroparesis.
Total Addressable Market (TAM)
The TAM for gastroparesis treatments is estimated to be several billion dollars annually. Evoke Pharma is positioned to capture a portion of this market with GIMOTI.
Upturn SWOT Analysis
Strengths
- Novel drug delivery (nasal spray)
- Targeted treatment for gastroparesis
- FDA approved product (GIMOTI)
Weaknesses
- Limited commercial infrastructure
- Reliance on a single product
- Requires patients to receive training of the nasal spray administration.
Opportunities
- Expanding GIMOTI market reach
- Potential for new formulations or indications
- Partnerships with larger pharmaceutical companies
Threats
- Competition from existing therapies (oral metoclopramide)
- Generic erosion
- Reimbursement challenges
- Potential adverse events or safety concerns
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- AZN
Competitive Landscape
Evoke Pharma faces competition from generic metoclopramide manufacturers and other pharmaceutical companies with GI products. GIMOTI's nasal delivery is a differentiating factor, but cost and market access can be challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been slow as Evoke Pharma transitioned from development to commercialization.
Future Projections: Analyst estimates suggest revenue growth as GIMOTI gains market traction.
Recent Initiatives: Focused sales and marketing efforts to increase GIMOTI prescriptions.
Summary
Evoke Pharma is a small pharmaceutical company focused on commercializing GIMOTI, a nasal spray for gastroparesis. Revenue growth is expected. The company faces challenges from established therapies and generics, but has a unique drug delivery mechanism. It is important to look out for more cash flows for better growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evoke Pharma Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2013-09-25 | Co-Founder, CEO & Director Mr. Matthew J. D'Onofrio MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 3 | Website https://www.evokepharma.com |
Full time employees 3 | Website https://www.evokepharma.com | ||
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.